|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 51/04 | |
| A61P 35/00 | |||
| A61P 39/00 | |||
| A61K 31/541 | |||
| A61K 31/4188 | |||
| A61K 31/225 |
| (11) | Patento numeris | 3193914 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 15840011.9 |
| Europos patento paraiškos padavimo data | 2015-09-04 | |
| (97) | Europos patento paraiškos paskelbimo data | 2017-07-26 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2021-01-20 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2015/048651 |
| Data | 2015-09-04 |
| (87) | Numeris | WO 2016/040179 |
| Data | 2016-03-17 |
| (30) | Numeris | Data | Šalis |
| 201462047546 P | 2014-09-08 | US |
| (72) |
BABICH, John W., US
HILLIER, Shawn, US
JOYAL, John, US
|
| (73) |
Molecular Insight Pharmaceuticals, Inc.,
One World Trade Center 47th Floor, Suite J, New York, New York 10007,
US
|
| (54) | ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER |
| ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER |